Drug intelligence / Profile preview

perindopril + indapamide + amlodipine + olmesartan + hydrochlorothiazide

Development stage
Unknown
Lead developer
Servier
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of five antihypertensive agents used for the management of high blood pressure. The components are: - Perindopril, an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation. - Indapamide, a thiazide-like diuretic that reduces blood volume and vascular resistance by promoting sodium and water excretion. - Amlodipine, a calcium channel blocker (CCB) that relaxes vascular smooth muscle and dilates arteries. - Olmesartan, an angiotensin II receptor blocker (ARB) that prevents vasoconstriction by blocking the action of angiotensin II on its receptor. - Hydrochlorothiazide, a thiazide diuretic with similar effects as indapamide. Each component targets different mechanisms involved in hypertension. Such combinations are used when monotherapy or dual therapy is insufficient for adequate blood pressure control. However, there is no evidence from available sources or clinical guidelines supporting the use or availability of this specific five-drug combination as a single product; rather, triple combinations such as perindopril/indapamide/amlodipine[1][2] and olmesartan/amlodipine/hydrochlorothiazide[3] exist separately.

02

Targets

ACE (Angiotensin Converting Enzyme)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on perindopril + indapamide + amlodipine + olmesartan + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on perindopril + indapamide + amlodipine + olmesartan + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call